Virtus Biotech Clinical Trials ETF (BBC)
| Assets | $50.55M |
| Expense Ratio | 0.65% |
| PE Ratio | n/a |
| Shares Out | 950,004 |
| Dividend (ttm) | $0.66 |
| Dividend Yield | 1.23% |
| Ex-Dividend Date | Dec 22, 2025 |
| Payout Frequency | Annual |
| Payout Ratio | n/a |
| Volume | 18,256 |
| Open | 55.56 |
| Previous Close | 55.34 |
| Day's Range | 53.18 - 55.56 |
| 52-Week Low | 22.43 |
| 52-Week High | 56.18 |
| Beta | 0.88 |
| Holdings | 131 |
| Inception Date | Dec 16, 2014 |
About BBC
Fund Home PageThe Virtus Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is issued by Virtus Investment Partners.
Top 10 Holdings
12.24% of assets| Name | Symbol | Weight |
|---|---|---|
| Amylyx Pharmaceuticals, Inc. | AMLX | 1.48% |
| First Tracks Biotherapeutics, Inc. | TRAX | 1.47% |
| AbCellera Biologics Inc. | ABCL | 1.34% |
| Xencor, Inc. | XNCR | 1.31% |
| Monopar Therapeutics Inc. | MNPR | 1.16% |
| AtaiBeckley Inc. | ATAI | 1.15% |
| MBX Biosciences, Inc. | MBX | 1.10% |
| uniQure N.V. | QURE | 1.10% |
| Replimune Group, Inc. | REPL | 1.08% |
| SELLAS Life Sciences Group, Inc. | SLS | 1.05% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 22, 2025 | $0.65544 | Dec 29, 2025 |
| Dec 20, 2024 | $0.23947 | Dec 27, 2024 |
| Dec 20, 2023 | $0.0823 | Dec 29, 2023 |
| Dec 20, 2017 | $0.29724 | Dec 27, 2017 |
| Dec 21, 2015 | $0.14733 | Dec 29, 2015 |
Performance
BBC had a total return of 136.40% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.15%.
News
June's Top ETFs: Biotech & China Semiconductors Surge
June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out...
Should Investors Follow Private Equity into Life Sciences?
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...
Novavax's 30% surge boosts biotech ETFs to best day in weeks
Exchange-traded funds with exposure to biotech stocks rocketed higher Tuesday on hopeful news about treatments for COVID-19.
Failure to Launch: The ETF Built to Fight the Coronavirus That Never Came to Be
Bloomberg's Eric Balchunas and Scarlet Fu break down the Virtus LifeSci Biotech Clinical Trials ETF (ticker: BBC) with Paul Yook, CIO of LifeSci Venture Partners.
Best Growth ETFs for Q1 2020
The best Growth ETFs for Q1 2020 are XLK, BBC, and VGT.
Best Healthcare ETFs for Q1 2020
The best Healthcare ETFs for Q1 2020 are BBC, SBIO, and KURE.